Biomerica, Inc. (BMRA)

Market Cap	54.65M
Revenue (ttm)	19.25M
Net Income (ttm)	-5.06M
Shares Out	13.10M
EPS (ttm)	-0.28
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	21,102
Open	4.06
Previous Close	4.07
Day's Range	4.02 - 4.17
52-Week Range	2.56 - 5.25
Beta	-0.53
Analysts	Buy
Price Target	13.26 (+218.0%)
Earnings Date	Jan 11, 2023

About BMRA

Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely...

• Industry: Health Care Equipment & Supplies
• Founded: 1971
• Employees: 64
• Stock Exchange: NASDAQ
• Ticker Symbol: BMRA

Full Company Profile

Financial Performance

In 2022, Biomerica's revenue was $18.87 million, an increase of 162.14% compared to the previous year's $7.20 million. Losses were -$4.53 million, -39.15% less than in 2021.

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for BMRA stock is "Buy." The 12-month stock price forecast is 13.26, which is an increase of 217.99% from the latest price.

Price Target

$13.26

(217.99% upside)

Analyst Consensus: Buy

Stock Forecasts